Elevated serum ICTP levels at admission independently predicted cardiac events in chronic heart failure patients with preserved left ventricular systolic function (HR 1.210).
Cohort (n=156)
No
Hazard Ratio: 1.21 (95% CI 1.013–1.446)
valor p: p=<0.05
BACKGROUND: Clinical markers to predict adverse outcome have not yet been established for patients with preserved left ventricular (LV) systolic function. The present study was designed to examine whether carboxy-terminal telopeptide of type I collagen (ICTP), a marker of collagen degradation, is useful for determining the prognosis of such patients. METHODS AND RESULTS: Serum levels of ICTP were measured at admission in 156 consecutive patients hospitalized for chronic heart failure (CHF). Patients were divided into 2 groups based on the LV ejection fraction (LVEF): reduced LV systolic function group (LVEF or =50%, n=64). In preserved LV systolic function group, cardiac event-free rates were significantly lower in high ICTP group than in low ICTP group (p<0.001). The area under the receiver operating characteristic curve of ICTP in the preserved LV systolic function group was markedly larger than that in the reduced LV systolic function group. Cox multivariate analysis also revealed that ICTP was an independent predictor of cardiac events in the preserved LV systolic function group. CONCLUSION: Serum ICTP level is highly reliable for risk stratifying CHF patients with preserved LV systolic function.
Kitahara et al. (Mon,) conducted a cohort in Chronic heart failure (n=156). Serum Carboxy-Terminal Telopeptide of Type I Collagen (ICTP) vs. Low ICTP levels was evaluated on Cardiac events (cardiac death or worsening heart failure requiring readmission) (HR 1.210, 95% CI 1.013-1.446, p=<0.05). Elevated serum ICTP levels at admission independently predicted cardiac events in chronic heart failure patients with preserved left ventricular systolic function (HR 1.210).